Are Circulating Cytokines Reliable Biomarkers for Amyotrophic Lateral Sclerosis?

Laura Moreno-Martinez, Ana Cristina Calvo *, Maria Jesús Muñoz and Rosario Osta

Laboratory of Genetics and Biochemistry (LAGENBIO), Faculty of Veterinary-IIS Aragon, IA2-CITA, CIBERNED, University of Zaragoza, Miguel Servet 177, 50013 Zaragoza, Spain; lauramm@unizar.es (L.M.-M.); mjmunoz@unizar.es (M.J.M.); osta@unizar.es (R.O.)

* Correspondence: accalvo@unizar.es

Received: 30 April 2019; Accepted: 3 June 2019; Published: 5 June 2019

Abstract: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that has no effective treatment. The lack of any specific biomarker that can help in the diagnosis or prognosis of ALS has made the identification of biomarkers an urgent challenge. Multiple panels have shown alterations in levels of numerous cytokines in ALS, supporting the contribution of neuroinflammation to the progressive motor neuron loss. However, none of them is fully sensitive and specific enough to become a universal biomarker for ALS. This review gathers the numerous circulating cytokines that have been found dysregulated in both ALS animal models and patients. Particularly, it highlights the opposing results found in the literature to date, and points out another potential application of inflammatory cytokines as therapeutic targets.

Keywords: cytokines; biomarkers; amyotrophic lateral sclerosis; blood; plasma; serum; cerebrospinal fluid; diagnosis; prognosis; inflammation

1. Introduction

Amyotrophic lateral sclerosis (ALS) is one of the most serious motor neuron diseases, and the most common adult motor neuron disease. It is characterized by loss of the cortex, brainstem, and spinal cord motor neurons (MNs), leading to muscle paralysis, and finally premature death due to respiratory failure within 2–5 years after diagnosis. Unfortunately, to date, no effective therapies able to cure the disease are available. More than 90% of ALS cases are sporadic with unknown causes. On the other hand, around 10% of ALS patients have a family history, involving mutations in a number of genes, such as Cu²⁺/Zn²⁺ superoxide dismutase 1 (SOD1), TAR DNA binding protein 43 (TDP-43), fused in sarcoma (FUS) and chromosome 9 open reading frame 72 (C9ORF72) repeat expansions [1]. These mutations found in ALS have allowed the development of animal models that are helpful in the study of this disease. One of the best characterized animal models for ALS is the SOD1G93A mouse model, which carries a G93A mutation (substitution of Glycine to Alanine at codon 93) in the human SOD1 gene, and presents both clinical and pathological characteristics of ALS patients [2].

The diagnosis of ALS is based on clinical tests and electrophysiological studies [3]. However, there is not a definitive diagnostic test for ALS, and the difficulty to reach it leads to the delay of diagnosis up to one year after the onset of symptoms. In addition, although the ALS Functional Rating Scale–Revised (ALSFRS-R) can functionally measure ALS progression [4], the prognosis in each patient still remains uncertain and challenging to anticipate.

Numerous mechanisms have been proposed to explain the degeneration of motor neurons, including misfolded protein aggregation and impaired degradation, glutamate excitotoxicity, increased oxidative stress, neuroinflammation and mitochondrial dysfunction [5]. However, the cause of motor neuron degeneration in ALS is still unclear.
2. The Necessity of Identifying Biomarkers for ALS

There is an imperious need to identify biomarkers that can help diagnose the disease at earlier stages and also to predict the course of the disease that allow following of more accurate therapeutic strategies. The ideal biomarker should be sensitive enough to diagnose ALS at the pre-symptomatic stage; specific for ALS and able to discriminate from other clinically similar neurodegenerative diseases; able to predict the progression of the disease in each patient; and easily accessible and applicable for all patients, despite their physical condition [6]. Although the origin of ALS remains unknown, multiple panels of biomarkers have been described in ALS patients and murine models to explain the progressive motor neuron loss and muscle atrophy, including imaging, electrophysiological and wet biomarkers [7].

Neuroimaging biomarkers allow a faithful visualization of the structural alterations happening in the tissue of study when comparing them with healthy tissues. Different brain imaging techniques have been used to detect these pathological changes in ALS patients, such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), diffusion tensor imaging (DTI) and positron emission tomography (PET) [8,9]. As a result of using these techniques, some pathological alterations regarding cortical atrophy, neuronal integrity and brain white matter abnormalities have been positively correlated with progression of the disease or resulted helpful in the diagnosis [10–13]. Although some promising imaging biomarkers have been found, none of them is fully sensitive and specific enough for ALS diagnosis or prognosis.

Numerous neurophysiologic biomarkers have been identified and proposed as biomarkers that help in the early diagnosis and monitoring of the progression of the disease [14]. Transcranial magnetic stimulation (TMS) technique can detect cortical hyperexcitability at early stages of the disease, which has been correlated with upper motor neuron dysfunction [15]. On the other hand, the course of ALS can be monitored by assessing lower motor neuron dysfunction using electrical impedance myography, axonal excitability testing, the motor unit number index and muscle ultrasonography [15–17]. However, despite the potential neurophysiological biomarkers found so far in assessing progression and early diagnosis, further studies should be conducted involving larger ALS cohorts [15].

Multiple molecular markers have been described in cerebrospinal fluid (CSF), plasma, serum, and even urine and saliva. Unlike CSF, the other fluids possess the advantage of being easily accessible and do not require invasive methods to obtain them, which is an important feature of the ideal biomarker. For this reason, over the last decades, several studies have been conducted to discover new biomarkers in biofluids that are derived from different pathological mechanisms of ALS [18–22]. The best considered biomarkers candidates are inflammatory molecules, metabolic markers and neurofilaments (NFs) [23,24].

To date, NFs are the most promising biomarkers for ALS. Particularly, both NF heavy chain (NFH) and NF light chain (NFL) levels measured in CSF and blood samples can be used to differentiate ALS patients from healthy subjects and/or other neurological diseases [25]. Furthermore, NFH and NFL levels in CSF were negatively correlated with disease duration, which address NFs as potential biomarkers for both diagnosis and prognosis of ALS [25].

Regarding inflammatory mediators, large panels of cytokines, including numerous interleukins, and immune cells, such as T regulatory cells (Treg), have been identified in CSF, plasma or serum, and have been correlated with faster or slower progression [26–28]. Cytokines and other inflammatory proteins will be discussed in depth in the following sections.

The study of metabolic alterations in ALS patients is an increasing field of knowledge and more studies are needed to identify more reliable biomarkers related to metabolic changes in different tissues, such as CSF, blood and muscle [29,30]. For example, findings about glutamate levels in CSF as a metabolic biomarker of disease progression in patients remain controversial [19]. Nevertheless, in plasma samples, glutamate levels were increased and correlated with the disease duration and with patients that exhibited spinal onset [31,32]. In addition, glutamate levels can be used as a metabolic biomarker in serum in response to drug intervention [33]. On the other hand, mass spectrometry has allowed the identification of different metabolic profiles where several amino acids have shown
different levels in blood and CSF of ALS patients compared to their controls; these metabolites include argine, lysine, serine and leucine, among others [19]. Other metabolites to consider are creatine and creatinine, which have been found dysregulated in CSF and blood [19,32], and used as molecular targets in a clinical trial [34]. Although altered metabolic profiles have been described in plasma samples of ALS patients, more reliable biomarkers that can contribute to disease progression and survival need to be identified [19].

microRNAs (miRNAs) are other potential biomarkers mainly due to their remarkably stability in body fluids. They have been found altered in CSF, plasma and serum from ALS patients and the SOD1G93A mouse model, such as MIR206, MIR143-3p, MIR338-3p [35–38]. Although some of these miRNAs are not specific for ALS, such as MIR206, it has been suggested that their combination could form part of a more integrative approach to help with ALS diagnosis and prognosis [38].

In urine, only one biomarker with prognostic value for ALS has been described, the extracellular domain of p75 neurotrophin receptor (p75ECD), whose levels showed an association with disease progression [39].

In spite of the fact that numerous potential biomarkers have been identified so far, none of them separately has sufficient sensitivity or specificity to become a universal biomarker for ALS. The lack of a robust biomarker is also reflected by some contradictory results and inconsistencies found in the literature, possibly due to patient heterogeneity and the complex scenario comprising this disease.

3. The Role of The Immune System in ALS

The dysregulation of the immune system in ALS results in increased central and peripheral inflammatory responses [40]. Neuroinflammation is characterized by microglial activation, astrogliosis, infiltration of T lymphocytes and monocytes, and overproduction of inflammatory cytokines [41–43]. Both innate and adaptive immune responses are involved in ALS progression and can promote either neuroprotection or neurotoxicity depending on disease stage, evidencing a dual role of inflammation in ALS [44]. Initially, there is an early anti-inflammatory or neuroprotective phase, where neurotrophic factors and anti-inflammatory cytokines, such as interleukin (IL)-4 and IL-10, are secreted by surrounding astrocytes and M2 microglia. As the disease progresses, the neuroprotective response changes to a cytotoxic phase due to the activation of M1 microglia and the consequent release of toxic factors, including reactive oxygen species (ROS) and pro-inflammatory cytokines, such as IL-1β and tumor necrosis factor (TNF)-α, which causes progressive injury to the MN [45].

Apart from microglia and astrocytes, T lymphocytes of the adaptive immune response also play a relevant role in the neurodegeneration observed in ALS. Especially, CD4+ T helper (Th) lymphocytes, including Th2 lymphocytes and Treg, are found in the early neuroprotective compensatory response; on the contrary, CD8+ T cytotoxic lymphocytes, such as Th1 and Th17 lymphocytes, are observed at later stages of the disease [45,46]. Both types of T lymphocytes have shown a dual role: Th1 and Th17 expression was found elevated in blood from ALS patients [47], whereas an upregulation of Treg in blood was associated with slower progression of the disease [48]. Similarly, increasing levels of Treg in animal models at early stages in the disease prolonged survival [49].

Other cells involved in MN degeneration are monocytes and macrophages. They have been found activated in peripheral blood and in CNS, especially in the spinal cord, due to the existent disruption of the blood-spinal cord barrier, in both ALS patients and murine models [50,51]. In line with this, some components of the complement system, which participate in the recruitment of mononuclear cells and macrophages, have been found elevated in CSF, blood, spinal cord and skeletal muscle from ALS patients or murine models [42,52,53]. However, the role of the complement system in ALS pathogenesis remains controversial due to the diverging results based on the great inter-individual differences during disease progression, although aberrant activation of the complement system is suggested to be involved in the pathophysiology in ALS animal models and patients [52].

More recently, the relevant role of the mutation C9orf72 in myeloid cells opened the door to altered microglial function that can link the connection between autoimmunity and ALS/FTD. Some studies on
heterozygous C9orf72 (C9orf72+/−) mice have suggested an altered myeloid cell function and systemic immunity. Accordingly, similar immunological consequences have been observed in ALS patients. Therefore, the loss of function of C9orf72 together with a combination of mutations of ALS/FTD genes could promote neurodegeneration [54]. Finally, the consequence of an altered microglia in both mutant SOD1 mice and patients is an amplified generation of pro-inflammatory cytokines that can trigger TNF-α-mediated apoptosis [55].

Despite the diverse humoral and cellular factors being found to be dysregulated, supporting the evident role of neuroinflammation in ALS pathology, to date it is still unclear how these inflammatory mediators can influence the progression of the disease and how they can be helpful in the diagnosis of ALS.

4. Dysregulation of Cytokines in Biofluids

A high number of studies have been conducted to find dysregulated cytokines in CSF and blood that can become potential biomarkers for ALS, mainly involving ALS patients, although few studies have been also performed in ALS animal models.

4.1. Interleukins

Interleukins comprise of a large family of cytokines that can exert both pro-inflammatory and anti-inflammatory actions. They are mainly synthesized by T cells, macrophages and endothelial cells promoting the development and differentiation of T and B cells, and hematopoietic cells. Numerous interleukins have been found elevated in CSF and/or blood from ALS patients compared to the levels measured in controls and/or patients with other non-inflammatory neurological disorders (OND): IL-1Ra, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-17A, IL-18 and IL-21 [26,47,56–70] (Table 1). Some of these interleukins follow the same pattern in the SOD1G93A model. Increasing levels of IL-2, IL-6, IL-10, IL-13 and IL-17B R in the transgenic (TG) mice are observed at an early stage of the disease [71]. In contrast, few studies reported decreasing levels of circulating IL-2, IL-5, IL-6 and IL-10 in ALS patients [58,63,72], whereas others found no significant differences in the levels of IL-2 and IL-6 in CSF or blood between ALS patients and their controls [73,74].

Table 1. Interleukins (IL) found dysregulated and proposed as biomarkers in biofluids from ALS animal models and patients.

| Cytokine | Subject | Biofluid | Significance | Reference |
|----------|---------|----------|--------------|-----------|
| IL-1Ra   | Patients| Blood    | Higher in ALS patients than in OND | [61] |
| IL-1β    | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|          |         | CSF, blood | Higher in ALS patients than controls and/or OND | [26,58,67,69,70] |
| IL-1β    | Mouse model | CF | Higher in ALS patients than controls and/or OND | [63] |
|          |   Blood | Blood | Predictors of poor survival | [26] |
| IL-4     | Patients | CSF, blood | Higher in ALS patients than controls and/or OND | [26,64] |
|          | CSF | CSF | Higher levels associated with slower disease progression | [64] |
| IL-5     | Patients | Blood | Higher in ALS patients than healthy controls | [26] |
|          |         | Blood | Lower in ALS patients than healthy controls | [63] |
| IL-6     | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|          | CSF, blood | Higher in ALS patients than controls and/or OND | [26,47,58,63,65–68,70] |
|          | Blood | Blood | Higher in ALS patients than controls | [72] |
|          | Blood | Blood | Rising levels associated with disease progression | [26] |
| IL-7     | Patients | CSF | Higher in ALS patients than in OND | [60,64] |
| IL-8     | Patients | CSF, blood | Higher in ALS patients than controls and/or OND | [26,57,63,65,66,68,70] |
| IL-9     | Patients | CSF | Higher in ALS patients than in OND | [60] |
Regarding the potential role of interleukins as prognostic biomarkers, rising levels of IL-4, IL-6 and IL-13 in CSF or blood from ALS patients were associated with disease progression and ALSFRS-R score [26,56,64] (Table 1). Additionally, levels of IL-2 in plasma correlated with poorer survival in both SOD1G93A mice and ALS patients [26,71]. In the animal model SOD1G93A, other interleukins found in plasma, IL-6 and IL-17B R, have been related to faster or slower progression of the disease [71].

Despite the large number of interleukins that seems to participate in the interplay of neuroinflammation in ALS pathogenesis, there is no definitive mediator that is being used in the clinical setting to help in diagnosis or predicting progression.

### 4.2. Tumor Necrosis Factors

TNF-α is a major pro-inflammatory cytokine. It is primarily secreted by activated macrophages and is involved in the induction of cytokine production, phagocyte cell activation, activation or expression of adhesion molecules, and growth stimulation [75]. In regards to ALS, increased TNF-α levels have been found in CSF and blood from ALS patients [26,60,65,68,69] (Table 2). On the contrary, additional studies have shown lower levels TNF-α in blood from ALS patients [72]. Furthermore, in some cases, TNF-α was not found altered in serum of ALS patients compared to controls [73] or its levels in neither CSF nor blood did not correlate with the severity and progression of the disease [74]. Due to these controversial results, its function in ALS pathogenesis is still uncertain likely due to its pleiotropic actions, as it can act in both pro- and anti-inflammatory responses [76].

### Table 2. Tumor necrosis factors (TNF) found dysregulated and proposed as biomarkers in biofluids from ALS animal models and patients.

| Cytokine     | Subject      | Biofluid          | Significance                                           | Reference |
|--------------|--------------|-------------------|--------------------------------------------------------|-----------|
| TNF-α        | Patients     | CSF; blood Blood  | Higher in ALS patients than controls and/or OND        | [26,60,65,68,69] |
|              |              |                   | Lower in ALS patients than controls                    | [72]      |
| TNFRSF1 (CD120) | Patients | Blood             | Higher in ALS patients than controls                   | [68,72]  |
| TNFRSF8 L (CD30 L) | Mouse model | Blood             | Higher in TG mice than WT mice                         | [71]     |
|              |              |                   | Lower in TG mice than WT mice                          | [71]     |
|              |              |                   | Higher levels associated with shorter survival          | [71]     |
| TNFRSF18 (GITR) | Mouse model | Blood             | Higher in TG mice than WT mice                         | [71]     |
|              |              |                   | Higher levels associated with shorter survival          | [71]     |
| TNFRSF19 (TROY) | Mouse model | Blood             | Higher in TG mice than WT mice                         | [71]     |
|              |              |                   | Negative correlation with longevity                     | [71]     |
| TNFSF11 (RANKL) | Mouse model | Blood             | Higher in TG mice than WT mice                         | [71]     |
Although TNF-α is the most studied factor of this family, other TNFs have been found dysregulated in ALS. For instance, blood levels of TNF Receptor Superfamily Member (TNFRSF)1A (CD120) were higher in ALS patients than controls [68,72] (Table 2). In the same line, other TNFs, including TNFRSF8 L, TNFRSF19 and TNF Superfamily Member (TNFSF)11, were elevated, and TNFRSF18 was reduced in the murine model SOD1G93A compared to the levels of WT mice at early stages of the disease [71]. In addition, the prognostic value of some of these factors has been evaluated, resulting in the association of high levels of TNFRSF18 and TNFRSF19 with poorer survival [71].

4.3. Interferons (IFN)

The only circulating IFN found dysregulated in ALS patients to date is IFN-γ. This cytokine takes part in both innate and adaptive immunity by participating in the activation of macrophages and in the adaptive T cell response [28]. In ALS patients, IFN-γ has been found elevated in both CSF and blood compared to the levels measured in controls and OND, and have been associated with faster progression and shorter survival [47,60,67,77] (Table 3). In contrast, other studies suggested lower levels of this factor in CSF and blood from ALS patients [26,58], which questions its role as a potential biomarker for ALS.

Table 3. Interferons (IFN) found dysregulated and proposed as biomarkers in biofluids from ALS patients.

| Cytokine | Subject | Biofluid | Significance | Reference |
|----------|---------|----------|--------------|-----------|
| IFN-γ    | Patients| CSF, blood| Higher in ALS than controls and/or OND patients | [47,60,67,77] |
|          |         |          | Lower in ALS than controls or OND patients | [26,58] |
|          |         |          | Positive correlation with DPR | [67,77] |
|          |         | CSF      | Higher levels associated with shorter overall survival. | [67] |

4.4. Colony Stimulating Factors (CSFs)

CSFs are responsible for stimulating proliferation and maturation of myeloid precursors. In particular, two of them have been linked to ALS: granulocyte (G)-CSF, involved in granulocyte production, and granulocyte-macrophage (GM)-CSF, participating in granulocyte, monocyte and eosinophil production. Both have been found increased in ALS patients in CSF and blood [58,60,64,67,69] (Table 4). In addition, levels of GM-CSF in blood negatively correlated with the duration of symptoms, which could help in the prognosis of the disease [78]. However, another study reported no significant differences in G-CSF levels in serum between ALS patients and controls or other neuropathies [73].

Table 4. Colony stimulating factors (CSFs) found dysregulated and proposed as biomarkers in biofluids from ALS patients.

| Cytokine | Subject | Biofluid | Significance | Reference |
|----------|---------|----------|--------------|-----------|
| G-CSF    | Patients| CSF, blood| Higher in ALS patients than controls and/or OND | [58,60,64,67,69] |
| GM-CSF   | Patients| CSF, blood| Higher in ALS patients than controls and/or OND | [58,67] |
|          |         | Blood    | Negative correlation with duration of symptoms | [78] |

4.5. Chemokines

The main function of pro-inflammatory chemokines is to direct immune cells to the site of inflammation via chemotaxis. As interleukins, this family encloses a vast group of both chemokines and chemokine receptors. Regarding ALS, increased expression of several members of chemokines was found in CSF or blood from ALS patients than in controls or OND: C-C motif chemokine ligand (CCL)2, CCL3, CCL4, CCL11, C-X-C motif chemokine ligand (CXCL)8 and CXCL10; in addition, their levels also correlated with ALSFRS-R score or disease progression rate (DPR) [57,58,60,64,67,69,78–80] (Table 5). In the case of CCL5, higher levels were also found in ALS patients in CSF [61], but not in blood, where its levels, together with CXCR5, were lower than in controls [72].
Table 5. Chemokines found dysregulated and proposed as biomarkers in biofluids from ALS animal models and patients.

| Cytokine | Subject | Biofluid | Significance | Reference |
|----------|---------|----------|--------------|-----------|
| CCL2 (MCP-1) | Patients | CSF, blood | Higher in ALS patients than controls and/or OND | [57,58,60,69,78,80] |
|           |         | Blood    | Negative correlation with ALSFRS-R score | [60,67] |
|           |         |          | Negative correlation with duration of symptoms | [78] |
| CCL3 (MIP-1α) | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|           |         | CSF, blood | Higher in ALS patients than controls and/or OND | [58,67,69,79] |
|           | Patients | CSF | Positive correlation with disease duration and negative correlation with DPR | [67,79] |
| CCL4 (MIP-1β) | Patients | CSF | Higher in ALS patients than controls and OND | [58,60,67,80] |
|           |         | Blood | Positive correlation with ALSFRS-R and disease duration, and negative correlations with DPR | [60] |
| CCL5 (RANTES) | Patients | CSF | Higher in ALS patients than in OND | [60] |
|           |         | Blood | Lower in ALS patients than controls | [72] |
| CCL11 (Eotaxin-1) | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|           |         | CSF, blood | Higher levels associated with shorter survival and negative correlation with longevity | [71] |
|           | Patients | CSF | Higher in ALS patients than in OND | [57,60,64] |
|           |         | Blood | Higher levels with slower DPR | [64] |
| CCL19 (MIP-3β) | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
| CCL21 (6Ckine) | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
| CXC5R | Patients | Blood | Lower in ALS patients than controls | [72] |
| CXCL8 | Patients | CSF | Higher in ALS patients than in OND | [60] |
|           |         | Blood | Negative correlation with ALSFRS-R score | [60] |
| CXCL10 | Patients | CSF | Higher in ALS patients than in OND | [60] |
|           |         | Blood | Negative correlation with DPR | [60] |

Similarly in the SOD1G93A model, four chemokines were upregulated at early stages in TG mice, CCL3, CCL11, CCL19 and CCL21, suggesting a dysregulation of these mediators before the onset of symptoms [71] (Table 5). In addition, CCL3 and CCL11 negatively correlated with the longevity of TG mice.

4.6. Other Cytokines and Proteins Related to Inflammation

Other proteins related to inflammation have been linked to ALS pathogenesis showing modified levels between ALS patients and their controls, and during disease progression (Table 6). Basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF)-BB were found elevated in CSF or blood in ALS patients [58,64,67]. On the contrary, other studies reported an association of high levels of bFGF with slower progression of the disease, which could be contradictory [67].

In the case of vascular endothelial growth factor (VEGF), higher levels were described in blood and CSF from ALS patients than in controls, whereas positive correlation with ALSFRS-R score and disease duration was reported, supporting the potential role of VEGF for ALS prognosis [58,60,67–69,81]. Low levels were also found in CSF from ALS patients during the first year of the disease [82]. In addition, an analysis combining VEGF with pNFH suggested a higher diagnostic yield [83].

Another cytokine altered in ALS is transforming growth factor beta (TGF-β), which is enrolled in the inhibition of T and B cell proliferation, hematopoiesis, and promotion of wound healing. In this case, higher levels were associated with faster progression of the disease in an ALS mouse model [84]. However, no differences were found in TGF-β levels in plasma from ALS patients [72].

Other proteins have also been shown to be altered in the SOD1G93A mouse model: activin receptor-like kinase (ALK)-1, galectin-1 and VEGF-D were elevated in plasma of TG mice [71]. In addition, rising levels of ALK-1 and galectin-1 in TG mice were associated with shorter survival [71]. In contrast, lower levels of galectin-3 in plasma were found in fast-progressing TG mice [84].
Interestingly, immunoglobulin G (IgG) antibodies have shown a relevant role for ALS prognosis. For instance, it has been reported that frequency and quantity of an IgG glycan is dependent on the ALS clinical stage in ALS animal models [85]. On the other hand, an increase in CSF IgG of the level of galactosylated structures was reported in ALS patients, showing a potential predictive value in the ROC analysis [86].

Table 6. Other cytokines and proteins related to inflammation found dysregulated and proposed as biomarkers in biofluids from ALS animal models and patients.

| Protein | Subject | Biofluid | Significance | Reference |
|---------|---------|----------|--------------|-----------|
| ALK-1   | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|         |         |         | Higher levels associated with shorter survival | [71] |
| bFGF    | Patients | CSF, blood | Higher in ALS patients than controls and/or OND | [58,64,67] |
|         |         | Blood  | Positive correlation with disease duration | [67] |
|         |         |         | Negative correlation with DPR | [67] |
| Galectin-1 | Mouse model | Blood | Higher in TG mice than WT mice | [71] |
|         |         |         | Higher levels associated with shorter survival and negative correlation with longevity | [71] |
| Galectin-3 | Mouse model | Blood | Lower in fast-progressing TG mice at pre-symptomatic and symptomatic than in WT mice | [84] |
| IgG     | Patients | CSF     | Increased level of galactosylated structures | [86] |
| PDGF-BB | Patients | CSF     | Higher in ALS patients than in OND | [64] |
| TGF-β   | Mouse model | Blood | Higher in slow-progressing TG mice and lower in fast-progressing TG mice at pre-symptomatic and symptomatic than in WT mice | [84] |
| VEGF    | Patients | CSF     | Low levels at early stages of ALS | [82] |
|         |         | CSF, blood | Higher in ALS patients than controls and/or OND | [58,60,67–69] |
|         |         |         | Positive correlation with ALSFRS-R score and disease duration | [60,67,81] |
|         |         |         | Negative correlation with DPR | [81] |
| VEGF-D  | Mouse model | Blood | Higher in TG mice than WT mice | [71] |

5. Cytokines as Biomarkers: Main Challenges

Over the last decades, many CSF and blood inflammatory cytokines have been found dysregulated in ALS, supporting the relevant contribution of neuroinflammation in the pathogenic mechanisms leading to motor neuron degeneration in ALS. However, the results shown are not always consistent in all the studies performed, which hampers the translation of a single cytokine as a biomarker to the clinical practice. As an example, it has been reported that the levels of certain cytokines in plasma from ALS patients were highly variable between the first and the second visit to the clinic, and even they did not show differences with healthy controls in some cases [63], exposing the great heterogeneity of the disease. In an attempt to deal with this issue, some authors have proposed that it would be more appropriate to identify panels of biomarkers, rather than focusing on a single target [87,88]. In this sense, panels of cytokines have been analyzed to help in a more accurate prediction of disease progression [89,90]. However, some authors suggest that these promising multivariate models should also include other clinical parameters, such as ALS type (sporadic or familial), disease stage, anatomical onset of motor neuron impairment and even age and gender [26,91].

Another problem that appears in the searching of circulating cytokines as biomarkers is the influence exerted by the action of environment and other factors surrounding the patient. For instance, the upregulation of some circulating cytokines, such as IL-6, IL-8, IL-10, G-CSF and TNF-α, has been linked to exercise [92], and others, including IL-6 and TNF-α, are elevated in a hypoxia status [93], which is a feature frequently found in ALS patients. In addition, the cytokine levels measured in blood in healthy individuals are not stable markers [94]. Cytokines play a relevant role in the immune system, and alterations in this system due to infections, injuries, tissue trauma or inflammation, which is inherent in ALS, can unbalance the immune system, even more under neurodegenerative conditions. This imbalance can promote an intra-individual variation that could explain the high
variability of cytokine levels observed in ALS [40,94]. Furthermore, in the context of ALS and FTD, the cytokine profile in blood is also challenging to interpret due to the disease state, environmental factors, and genetic background of the individuals that can lead to controversial results [40].

Therefore, the consideration of circulating cytokines and other circulating targets as biomarkers is being increasingly questioned, mainly due to the opposing and irreproducible results that have been shown in different studies [95]. Additionally, the underlying causes, such as lack of sensitivity, unsuitable normalization or variations in sample handling, together with the difficulties in cytokine assays that are not performed in routine clinical methodology, establish this issue as a real challenge. In an attempt to address this problem, Otto et al. proposed a roadmap for biomarker discovery and provided standard operating procedures that could allow multicenter collaboration and validation of the neurochemical markers discovered in ALS to facilitate their translation to the clinic [96]. In this line, multicenter studies can also shed light on this controversial issue by confirming the results among different centers in the world, as demonstrated in several multicenter studies performed with ALS patients [97–99]. Accordingly, it could be interesting to contemplate multicenter studies regarding the most promising inflammatory mediators, which could be helpful to validate them.

6. Design of Therapeutic Approaches Targeting Inflammation

Given the number of cytokines found dysregulated in ALS, in the last decades many studies have translated the focus in assessing the potential role of those cytokines in therapies counteracting inflammation in ALS. In fact, there are currently several clinical trials involving therapies targeting neuroinflammation in ALS [42]. G-CSF is one of the targets that have provided beneficial results when administrated in both animal models and patients [100–102]. Similarly, other studies have shown that the administration of IL-33 or IFN-γ antibody delayed the disease onset and the motor decline, respectively, in an ALS mouse model [103,104]. However, there are also controversial results when translating the findings obtained in the animal model to ALS patients. For example, therapies using thalidomide and lenalidomide to inactivate TNF-α prolonged lifespan and enhanced the motor performance in the animal model [105,106]; in contrast, thalidomide treatment did not cause any improvement when administrated to ALS patients [107]. Regarding IL-6, transgenic mice deficient in IL-6 did not show any improvement, as well as a blocking IL-6 therapy in an ALS mouse model [108,109].

In view of this, it seems evident that therapies targeting a single factor could not provide meaningful benefits in ALS patients, as well as in the search for a reliable biomarker. Hooten et al. address questions on why these kinds of therapies are failing, highlighting that it could be too late when they are applied, or that therapies might not hit appropriate targets [45].

Recently, cell-based therapies are emerging as a promising strategy to modulate the immune system in ALS as they can influence different key immune targets. For instance, experimental treatments based on mesenchymal stem cells (MSCs) have shown to raise concentrations of neurotrophic factors, and elevate anti-inflammatory cytokines, which reduces neuroinflammation [43,110]. On the other hand, therapies targeting Treg, which were associated with disease progression [27,111], have also shown interesting results in ALS patients [112].

7. Conclusions

ALS is a multifactorial disease where different pathological mechanisms direct or indirectly contribute to the degeneration of motor neurons. Neuroinflammation is one of these mechanisms investigated, since the involvement of many inflammatory mediators in this disease has been widely reported. However, the identification of specific cytokines to help in the diagnosis and also to predict the progression of the disease in ALS patients is challenging due to the great heterogeneity found in this disease. In addition, cytokines are variable and susceptible to the disease stage and to environmental factors surrounding ALS patients, who do not show an equal status of neuroinflammation. Consequently, the different pro and anti-inflammatory cytokines along the disease progression should be further studied to understand its time point activation and its relation to
other molecular and clinical mediators in ALS to finally provide a better monitorization of disease progression. In this sense, cytokines could be helpful in improving the stratification of ALS patients according to their inflammatory status, enabling more accurate therapeutic approaches targeting these key immune factors.

**Author Contributions:** Conceptualization, A.C.C., L.M.-M., M.M. and R.O.; investigation, A.C.C., L.M.-M.; resources, A.C.C., L.M.-M.; writing—original draft preparation, L.M.-M.; writing—review and editing, A.C.C. and R.O.; visualization, A.C.C., M.J.M. and R.O.; supervision, A.C.C., M.J.M. and R.O.; project administration, A.C.C. and R.O.; funding acquisition, A.C.C. and R.O.

**Funding:** This research was funded by Instituto de Salud Carlos III (Grant PI17/00949) and Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa” from the European Union, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED-612), Fundación FEDER (Federación Española de Enfermedades Raras), Consolidated Groups from Gobierno de Aragón, Fundación Sesé and Plataforma afectados por la ELA. L.M.-M. is supported by Departamento de Industria e Innovación from Gobierno de Aragón and Fondo Social Europeo.

**Acknowledgments:** We acknowledge Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa” from the European Union, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Fundación FEDER (Federación Española de Enfermedades Raras), Consolidated Groups from Gobierno de Aragón, Fondo Social Europeo, Fundación Sesé and Plataforma afectados por la ELA for their funding.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

| Abbreviation   | Description                                      |
|----------------|--------------------------------------------------|
| ALK-1          | Activin receptor-like kinase 1                   |
| ALS            | Amyotrophic lateral sclerosis                    |
| ALSFRS-R       | Amyotrophic lateral sclerosis functional rating scale-revised |
| bFGF           | Basic fibroblast growth factor                   |
| C9ORF72        | Chromosome 9 open reading frame 72               |
| CCL            | C-C motif chemokine ligand                       |
| CSF            | Cerebrospinal fluid                              |
| CSFs           | Colony stimulating factors                       |
| CXCL           | C-X-C motif chemokine ligand                     |
| CXCR5          | C-X-C motif chemokine receptor 5                 |
| DPR            | Disease progression rate                         |
| DTI            | Diffusion tensor imaging                         |
| FUS            | Fused in sarcoma                                 |
| G-CSF          | Granulocyte colony stimulating factor            |
| GITR           | Glucocorticoid-induced TNFR-related protein      |
| GM-CSF         | Granulocyte-macrophage colony stimulating factor |
| IL             | Interleukin                                      |
| IFN            | Interferons                                      |
| IgG            | Immunoglobulin G                                 |
| MCP-1          | Monocyte chemotactic protein-1                   |
| miRNAs         | microRNAs                                        |
| MIP            | Macrophage inflammatory protein                  |
| MN(s)          | Motor neuron(s)                                  |
| MRI            | Magnetic resonance imaging                       |
| MRS            | Magnetic resonance spectroscopy                  |
| NFs            | Neurofilaments                                   |
| NFH            | Neurofilament heavy chain                        |
| NFL            | Neurofilament light chain                        |
| OND            | Other non-inflammatory neurological disorders     |
| p75ECD         | Extracellular domain of p75 neurotrophin receptor |
| PDGF-BB        | Platelet-derived growth factor BB                |
PET Positron emission tomography
RANKL Receptor activator of nuclear factor kappa-B ligand
ROS Reactive oxygen species
SOD1 Superoxide dismutase 1
TDP-43 TAR DNA binding protein 43
TGF-β Transforming growth factor beta
TG Transgenic
Th T helper
TMS Transcranial magnetic stimulation
TNF Tumor necrosis factor
TNFRSF TNF receptor superfamily member
TNFSF TNF superfamily member
Treg Regulatory T cell
TROY Tumor necrosis factor receptor superfamily member 19
VEGF Vascular endothelial growth factor
WT Wildtype

References
1. Martin, S.; Al Khleifat, A.; Al-Chalabi, A. What causes amyotrophic lateral sclerosis? *F1000Res* 2017, 6, 371. [CrossRef]
2. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polychow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. *Science* 1994, 264, 1772–1775. [CrossRef] [PubMed]
3. Al-Chalabi, A.; Hardiman, O.; Kiernan, M.C.; Chio, A.; Rix-Brooks, B.; van den Berg, L.H. Amyotrophic lateral sclerosis: Moving towards a new classification system. *Lancet Neurol.* 2016, 15, 1182–1194. [CrossRef]
4. Cedarbaum, J.M.; Stambler, N.; Malta, E.; Fuller, C.; Hilt, D.; Thurmond, B.; Nakanishi, A. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). *J. Neurol. Sci.* 1999, 169, 13–21. [CrossRef]
5. Turner, M.R.; Hardiman, O.; Benatar, M.; Brooks, B.R.; Chio, A.; de Carvalho, M.; Ince, P.G.; Lin, C.; Miller, R.G.; Mitsumoto, H.; et al. Controversies and priorities in amyotrophic lateral sclerosis. *Lancet Neurol.* 2013, 12, 310–322. [CrossRef]
6. Turner, M.R.; Kiernan, M.C.; Leigh, P.N.; Talbot, K. Biomarkers in amyotrophic lateral sclerosis. *Lancet Neurol.* 2009, 8, 94–109. [CrossRef]
7. Verber, N.S.; Shepheard, S.R.; Sassani, M.; McDonough, H.E.; Moore, S.A.; Alix, J.J.P.; Wilkinson, I.D.; Jenkins, T.M.; Shaw, P.J. Biomarkers in Motor Neuron Disease: A State of the Art Review. *Front. Neurol.* 2019, 10, 291. [CrossRef]
8. Menke, R.A.; Agosta, F.; Grosskreutz, J.; Filippi, M.; Turner, M.R. Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. *Neurotherapeutics* 2017, 14, 11–23. [CrossRef]
9. Mazon, M.; Vazquez Costa, J.F.; Ten-Esteve, A.; Marti-Bonmati, L. Imaging Biomarkers for the Diagnosis and Prognosis of Neurodegenerative Diseases. The Example of Amyotrophic Lateral Sclerosis. *Front. Neurosci.* 2018, 12, 784. [CrossRef]
10. Simon, N.G.; Turner, M.R.; Vucic, S.; Al-Chalabi, A.; Shefner, J.; Lomen-Hoerth, C.; Kiernan, M.C. Quantifying disease progression in amyotrophic lateral sclerosis. *Ann. Neurol.* 2014, 76, 643–657. [CrossRef]
11. Ferraro, P.M.; Agosta, F.; Riva, N.; Copetti, M.; Spinelli, E.G.; Falzone, Y.; Soraru, G.; Comi, G.; Chio, A.; Filippi, M. Multimodal structural MRI in the diagnosis of motor neuron diseases. *Neuroimage Clin.* 2017, 16, 240–247. [CrossRef] [PubMed]
12. Barratt, A.W.; Gabel, M.C.; Cercignani, M.; Leigh, P.N. Emerging Magnetic Resonance Imaging Techniques and Analysis Methods in Amyotrophic Lateral Sclerosis. *Front. Neurol.* 2018, 9, 1065. [CrossRef] [PubMed]
13. Steinbach, R.; Gaur, N.; Stubendorff, B.; Witte, O.W.; Grosskreutz, J. Developing a Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis: Multi-Center Data Sharing and the Road to a “Global Cohort”. *Front. Neurol.* 2018, 9, 1055. [CrossRef] [PubMed]
14. Huynh, W.; Dharmadasa, T.; Vucic, S.; Kiernan, M.C. Functional Biomarkers for Amyotrophic Lateral Sclerosis. *Front. Neurol.* 2019, 9, 1141. [CrossRef] [PubMed]
15. Vucic, S.; Ruthkove, S.B. Neurophysiological biomarkers in amyotrophic lateral sclerosis. *Curr. Opin. Neurol.* 2018, 31, 640–647. [CrossRef] [PubMed]
16. Martinez-Paya, J.J.; Rios-Diaz, J.; Medina-Mirapeix, F.; Vazquez-Costa, J.F.; Del Bano-Aledo, M.E. Monitoring Progression of Amyotrophic Lateral Sclerosis Using Ultrasound Morpho-Textural Muscle Biomarkers: A Pilot Study. *Ultrasound Med. Biol.* 2018, 44, 102–109. [CrossRef]
17. Rios-Diaz, J.; Del Bano-Aledo, M.E.; Tembl-Ferrairo, J.I.; Chumillas, M.J.; Vazquez-Costa, J.F.; Martinez-Paya, J.J. Quantitative neuromuscular ultrasound analysis as biomarkers in amyotrophic lateral sclerosis. *Eur. Radiol.* 2019. [CrossRef] [PubMed]
18. Tarasiuk, J.; Kulakowska, A.; Drozdowski, W.; Kornhuber, J.; Lewczuk, P. CSF markers in amyotrophic lateral sclerosis. *J. Neural Transm.* (Vienna) 2012, 119, 747–757. [CrossRef]
19. Vu, L.T.; Bowser, R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. *Neurotherapeutics* 2017, 14, 119–134. [CrossRef]
20. Majumder, V.; Gregory, J.M.; Barria, M.A.; Green, A.; Pal, S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: A systematic review and meta-analysis. *BMC Neurol.* 2018, 18, 90. [CrossRef]
21. Bjornevik, K.; Zhang, Z.; O’Reilly, E.J.; Berry, J.D.; Clish, C.B.; Deik, A.; Jeanfavre, S.; Kato, I.; Kelly, R.S.; Kolonel, L.N.; et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. *Neurology* 2019. [CrossRef] [PubMed]
22. Calvo, A.C.; Atencia Cibreiro, G.; Torre Merino, P.; Roy, J.F.; Galiana, A.; Juarez Ruftian, A.; Cano, J.M.; Martin, M.A.; Moreno, L.; Larrodé, P.; et al. Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis. *Aging Dis.* 2019, 10, 278. [CrossRef] [PubMed]
23. Costa, J.; de Carvalho, M. Emerging molecular biomarker targets for amyotrophic lateral sclerosis. *Clin. Chim. Acta* 2016, 455. [CrossRef] [PubMed]
24. Floeter, M.K.; Gendron, T.F. Biomarkers for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Associated With Hexanucleotide Expansion Mutations in C9orf72. *Front. Neurol.* 2018, 9, 1063. [CrossRef] [PubMed]
25. Xu, Z.; Henderson, R.D.; David, M.; McCombe, P.A. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *PLoS ONE* 2016, 11, e0164625. [CrossRef] [PubMed]
26. Lu, C.H.; Allen, K.; Oei, F.; Kuhle, J.; Tree, T.; Fratta, P.; Sharma, N.; Sidle, K.; Howard, R.; et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. *Neurology Neuroimmunol. Neuroinflamm.* 2016, 3, e244. [CrossRef]
27. Beers, D.R.; Zhao, W.; Wang, J.; Zhang, X.; Wen, S.; Keal, D.; Thonhoff, J.R.; Alsuliman, A.S.; Shpall, E.J.; Rezvani, K.; et al. ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. *JCI Insight* 2017, 2, e89530. [CrossRef]
28. Michaelson, N.; Facchin, D.; Bradley, W.; Stommel, E. Cytokine expression levels in ALS: A potential link between inflammation and BMAA-triggered protein misfolding. *Cytokine Growth Factor Rev.* 2017, 37, 81–88. [CrossRef]
29. Blasco, H.; Pattin, F.; Madji Hounoum, B.; Gordon, P.H.; Vourc’h, P.; Andres, C.R.; Corcia, P. Metabolomics in amyotrophic lateral sclerosis: How far can it take us? *Eur. J. Neurol.* 2016, 23, 447–454. [CrossRef]
30. Lanznaster, D.; de Assis, D.R.; Corcia, P.; Pradat, P.F.; Blasco, H. Metabolomics Biomarkers: A Strategy Toward Therapeutics Improvement in ALS. *Front. Neurol.* 2018, 9, 1126. [CrossRef]
31. Andreadou, E.; Kapaki, E.; Kokotis, P.; Paraskevas, G.P.; Katsaros, N.; Libitaki, G.; Zis, V.; Sfagos, C.; Vassilopoulos, D. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: The effect of riluzole treatment. *Clin. Neurol. Neurosurg.* 2008, 110, 222–226. [CrossRef] [PubMed]
32. Lawton, K.A.; Brown, M.V.; Alexander, D.; Li, Z.; Wulff, J.E.; Lawson, R.; Jaffa, M.; Milburn, M.V.; Ryals, J.A.; Bowser, R.; et al. Northeast ALS Consortium Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 2018, 19, 640–647. [CrossRef] [PubMed]
33. Niebroj-Dobosz, I.; Janik, P.; Kwiecinski, H. Effect of Riluzole on serum amino acids in patients with amyotrophic lateral sclerosis. *Acta Neurol. Scand.* 2002, 106, 39–43. [CrossRef] [PubMed]
34. Bozik, M.E.; Mitsumoto, H.; Brooks, B.R.; Rudnicki, S.A.; Moore, D.H.; Zhang, B.; Ludolph, A.; Cudkowicz, M.E.; van den Berg, L.H.; Mather, J.; et al. A post hoc analysis of subgroup outcomes and creatine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 2014, 15, 406–413. [CrossRef] [PubMed]
35. Toivonen, J.M.; Manzano, R.; Olivan, S.; Zaragoza, P.; Garcia-Redondo, A.; Osta, R. MicroRNA-206: A potential circulating biomarker candidate for amyotrophic lateral sclerosis. *PLoS ONE* **2014**, *9*, e89065. [CrossRef] [PubMed]

36. Benigni, M.; Ricci, C.; Jones, A.R.; Giannini, F.; Al-Chalabi, A.; Battistini, S. Identification of miRNAs as Potential Biomarkers in Cerebrospinal Fluid from Amyotrophic Lateral Sclerosis Patients. *Neuromolecular Med.* **2016**, *18*, 551–560. [CrossRef] [PubMed]

37. Ricci, C.; Marzocchi, C.; Battistini, S. MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis. *Cells* **2018**, *7*, 219. [CrossRef] [PubMed]

38. Joilin, G.; Leigh, P.N.; Newbury, S.F.; Hafezparast, M. An Overview of MicroRNAs as Biomarkers of ALS. *Front. Neurol.* **2019**, *10*, 186. [CrossRef]

39. Shepheard, S.R.; Wuu, J.; Cardoso, M.; Wiklendt, L.; Dinning, P.G.; Chataway, T.; Schultz, D.; Benatar, M.; Rogers, M.L. Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS. *Neurology* **2017**, *88*, 1137–1143. [CrossRef]

40. McCauley, M.E.; Baloh, R.H. Inflammation in ALS/FTD pathogenesis. *Acta Neuropathol*. **2018**. [CrossRef]

41. Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. *Science* **2016**, *353*, 777–783. [CrossRef] [PubMed]

42. Liu, J.; Wang, F. Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications. *Front. Immunol.* **2017**, *8*, 1005. [CrossRef] [PubMed]

43. Beers, D.R.; Appel, S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. *Lancet Neurol.* **2019**, *18*, 211–220. [CrossRef]

44. Zhao, W.; Beers, D.R.; Appel, S.H. Immune-mediated mechanisms in the pathoproggression of amyotrophic lateral sclerosis. *J. Neuroimmune Pharmacol.* **2013**, *8*, 888–899. [CrossRef] [PubMed]

45. Hooten, K.G.; Beers, D.R.; Zhao, W.; Appel, S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. *Neurotherapeutics* **2015**, *12*, 364–375. [CrossRef] [PubMed]

46. Murdock, B.J.; Bender, D.E.; Segal, B.M.; Feldman, E.L. The dual roles of immunity in ALS: Injury overrides protection. *Neurobiol. Dis.* **2015**, *5*, 64–79. [CrossRef] [PubMed]

47. Saresella, M.; Piancone, F.; Tortorella, P.; Marventano, I.; Gatti, A.; Caputo, D.; Lunetta, C.; Corbo, M.; Rovaris, M.; Clerici, M. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. *Clin. Immunol.* **2015**, *148*, 79–88. [CrossRef]

48. Henkel, J.S.; Beers, D.R.; Wen, S.; Rivera, A.L.; Toennis, K.M.; Appel, J.E.; Zhao, W.; Moore, D.H.; Powell, S.Z.; Appel, S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. *EMBO Mol. Med.* **2013**, *5*, 64–79. [CrossRef] [PubMed]

49. Beers, D.R.; Henkel, J.S.; Zhao, W.; Wang, J.; Huang, A.; Wen, S.; Liao, B.; Appel, S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. *Brain* **2011**, *134*, 1293–1314. [CrossRef]

50. Zondler, L.; Muller, K.; Khalaji, S.; Bliednerhauser, C.; Ruf, W.P.; Grozdanov, V.; Thiemann, M.; Fundel-Clemes, K.; Freischmidt, A.; Holzmann, K.; et al. Peripheral monocytes are functionally altered and invade the CNS in ALS patients. *Acta Neuropathol.* **2016**, *132*, 391–411. [CrossRef]

51. Gasco, S.; Zaragoza, P.; Garcia-Redondo, A.; Calvo, A.C.; Osta, R. Inflammatory and non-inflammatory monocytes as novel prognostic biomarkers of survival in SOD1G93A mouse model of Amyotrophic Lateral Sclerosis. *PLoS ONE* **2017**, *12*, e0184626. [CrossRef] [PubMed]

52. Kjaeldgaard, A.L.; Pilely, K.; Olsen, K.S.; Pedersen, S.W.; Lauritsen, A.O.; Moller, K.; Garred, P. Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis. *Mol. Immunol.* **2018**, *102*, 14–25. [CrossRef] [PubMed]

53. Parker, S.E.; Hanton, A.M.; Stefanou, S.N.; Noakes, P.G.; Woodruff, T.M.; Lee, J.D. Revisiting the role of the innate immune complement system in ALS. *Neuropsychobiology Dis.* **2019**, *127*, 223–232. [CrossRef] [PubMed]

54. Lall, D.; Baloh, R.H. Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia. *J. Clin. Invest.* **2017**, *127*, 3250–3258. [CrossRef] [PubMed]

55. Glass, C.K.; Saijo, K.; Winner, B.; Marchetto, M.C.; Gage, F.H. Mechanisms underlying inflammation in neurodegeneration. *Cell* **2010**, *140*, 918–934. [CrossRef] [PubMed]

56. Shi, N.; Kawano, Y.; Tateishi, T.; Kikuchi, H.; Oseogawa, M.; Ohyagi, Y.; Kira, J. Increased IL-13-producing T cells in ALS: Positive correlations with disease severity and progression rate. *J. Neuroimmunol.* **2007**, *182*, 232–235. [CrossRef] [PubMed]
57. Kuhle, J.; Lindberg, R.L.; Regeniter, A.; Mehling, M.; Steck, A.J.; Kappos, L.; Czaplinski, A. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. *Eur. J. Neurol.* **2009**, *16*, 771–774. [CrossRef]

58. Mitchell, R.M.; Freeman, W.M.; Randazzo, W.T.; Stephens, H.E.; Beard, J.L.; Simmons, Z.; Connor, J.R. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. *Neurology* **2009**, *72*, 14–19. [CrossRef]

59. Fiala, M.; Chattopadhay, M.; La Cava, A.; Tse, E.; Liu, G.; Lourenco, E.; Eskin, A.; Liu, P.T.; Maggiantay, L.; Tse, S.; et al. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. *J. Neuroimmunol.* **2010**, *7*, 76. [CrossRef]

60. Tateishi, T.; Yamasaki, R.; Tanaka, M.; Matsushita, T.; Kikuchi, H.; Isobe, N.; Ohyagi, Y.; Kira, J. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. *J. Neuroimmunol.* **2010**, *222*, 76–81. [CrossRef]

61. Furukawa, T.; Matsui, N.; Fujita, K.; Miyashiro, A.; Nodera, H.; Izumi, Y.; Shimizu, F.; Miyamoto, K.; Takahashi, Y.; Kanda, T.; et al. Increased proinflammatory cytokines in sera of patients with multifocal motor neuropathy. *J. Neurol. Sci.* **2014**, *346*, 75–79. [CrossRef] [PubMed]

62. Italiani, P.; Carlesi, C.; Giungato, P.; Puxeddu, I.; Borroni, B.; Bossu, P.; Migliorini, P.; Siciliano, G.; Boraschi, D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. *J. Neuroimmunflammation* **2014**, *11*, 94. [CrossRef] [PubMed]

63. Ehrhart, J.; Smith, A.J.; Kuzmin-Nichols, N.; Zesiewicz, T.A.; Jahan, I.; Shytte, R.D.; Kim, S.H.; Sanberg, C.D.; Vu, T.H.; Gooch, C.L.; et al. Humoral factors in ALS patients during disease progression. *J. Neuroinflamm.* **2015**, *12*, 127. [CrossRef] [PubMed]

64. Furukawa, T.; Matsui, N.; Fujita, K.; Nodera, H.; Shimizu, F.; Miyamoto, K.; Takahashi, Y.; Kanda, T.; Kusunoki, S.; Izumi, Y.; et al. CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. *Neurol. Neuroimmunmunol. Neuroinflamm.* **2015**, *2*, e138. [CrossRef] [PubMed]

65. Ngo, S.T.; Steyn, F.J.; Huang, L.; Mantovani, S.; Pfluger, C.M.; Woodruff, T.M.; O’Sullivan, J.D.; Henderson, R.D.; McCombe, P.A. Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. *J. Neurosci.* **2015**, *357*, 22–27. [CrossRef]

66. Blasco, H.; Garcon, G.; Patin, F.; Veyrat-Durebex, C.; Boyer, J.; Devos, D.; Vourc’h, P.; Andres, C.R.; Corcia, P. Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study. *Can. J. Neurol. Sci.* **2017**, *44*, 90–95. [CrossRef]

67. Guo, J.; Yang, X.; Gao, L.; Zang, D. Evaluating the levels of CSF and serum factors in ALS. *Brain Behav.* **2017**, *7*, e00637. [CrossRef]

68. Hu, Y.; Cao, C.; Qin, X.Y.; Yu, Y.; Yuan, J.; Zhao, Y.; Cheng, Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. *Sci. Rep.* **2017**, *7*, 9094. [CrossRef]

69. Chen, X.; Hu, Y.; Cao, Z.; Liu, Q.; Cheng, Y. Cerebrospinal Fluid Inflammatory Cytokine Aberrations in Alzheimer’s Disease, Parkinson’s Disease and Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *Front. Immunol.* **2018**, *9*, 2122. [CrossRef]

70. Prado, L.G.R.; Rocha, N.P.; de Souza, L.C.; Bicalho, I.C.S.; Braz, N.F.T.; Vieira, E.L.M.; Teixeira, A.L. Longitudinal assessment of clinical and inflammatory markers in patients with amyotrophic lateral sclerosis. *J. Neurol. Sci.* **2018**, *394*, 69–74. [CrossRef]

71. Moreno-Martinez, L.; de la Torre, M.; Toivonen, J.M.; Zaragoza, A.; Calvo, A.C.; Osta, R. Circulating Cytokines Could Not Be Good Prognostic Biomarkers in a Mouse Model of Amyotrophic Lateral Sclerosis. *Front. Immunol.* **2019**, *10*, 801. [CrossRef] [PubMed]

72. Andres-Benito, P.; Moreno, J.; Dominguez, R.; Aso, E.; Povedano, M.; Ferrer, I. Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis. *Front. Neurol.* **2017**, *8*, 546. [CrossRef] [PubMed]

73. Vlam, L.; Stam, M.; de Jager, W.; Cats, E.A.; van den Berg, L.H.; van der Pol, W.L. Cytokine profiles in multifocal motor neuropathy and progressive muscular atrophy. *J. Neuroinmunol.* **2015**, *286*, 1–4. [CrossRef] [PubMed]

74. Martinez-Merino, L.; Iridoy, M.; Galbete, A.; Roldan, M.; Rivero, A.; Acha, B.; Irun, P.; Canosa, C.; Pocovi, M.; Mendioroz, M.; et al. Evaluation of Chitotriosidase and CC-Chemokine Ligand 18 as Biomarkers of Microglia Activation in Amyotrophic Lateral Sclerosis. *Neurodegener Dis.* **2018**, *18*, 208–215. [CrossRef] [PubMed]

75. Turner, M.D.; Nedjai, B.; Hurst, T.; Pennington, D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochim. Biophys. Acta* **2014**, *1843*, 2563–2582. [CrossRef] [PubMed]
76. Tortarolo, M.; Lo Coco, D.; Veglianeese, P.; Vallarola, A.; Giordana, M.T.; Marcon, G.; Beghi, E.; Poloni, M.; Strong, M.J.; Iyer, A.M.; et al. Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFalpha. *Mediators Inflamm.* 2017, 2017, 2985051. [CrossRef]  

77. Liu, J.; Gao, L.; Zang, D. Elevated Levels of IFN-gamma in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis. *PLoS ONE* 2015, 10, e0136937.  

78. Mitchell, R.M.; Simmons, Z.; Beard, J.L.; Stephens, H.E.; Connor, J.R. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. *Muscle Nerve* 2010, 42, 95–103. [CrossRef]  

79. Yang, X.; Gao, L.; Wu, X.; Zhang, Y.; Zang, D. Increased levels of MIP-1alpha in CSF and serum of ALS. *Acta Neurol. Scand.* 2016, 134, 94–100. [CrossRef]  

80. Martinez, H.R.; Escamilla-Ocanas, C.E.; Camara-Lemarroy, C.R.; Gonzalez-Garza, M.T.; Moreno-Cuevas, J.; Garcia Sarreoon, M.A. Increased cerebrospinal fluid levels of cytokines monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 beta (MIP-1beta) in patients with amyotrophic lateral sclerosis. *Neurologia* 2017.  

81. Gao, L.; Zhou, S.; Cai, H.; Gong, Z.; Zang, D. VEGF levels in CSF and serum in mild ALS patients. *J. Neurol. Sci.* 2014, 346, 216–220. [CrossRef] [PubMed]  

82. Devos, D.; Moreau, C.; Lassalle, P.; Perez, T.; De Seze, J.; Brunaud-Danel, V.; Destee, A.; Tonnel, A.B.; Just, N. Low levels of the vascular endothelial growth factor in CSF from early ALS patients. *Neurology* 2004, 62, 2127–2129. [CrossRef] [PubMed]  

83. Goncalves, M.; De Carvalho, M.; Peixoto, C.; Alves, P.; Barreto, C.; Oliva, A.; Pinto, S.; Laborinho-Pronto, A.; Gromicho, M.; Costa, J. Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 2017, 18, 134–136. [CrossRef] [PubMed]  

84. Zubiri, I.; Lombardi, V.; Bremang, M.; Mitra, V.; Nardo, G.; Aduitori, R.; Lu, C.H.; Leoni, E.; Yip, P.; Yildiz, O.; et al. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. *Mol. Neurodegener* 2018, 13, 60. [CrossRef] [PubMed]  

85. Edri-Brami, M.; Sharoni, H.; Hayoun, D.; Skutelsky, L.; Nemirovsky, A.; Porgador, A.; Lichtenstein, R.G. Development of stage-dependent glycans on the Fc domains of IgG antibodies of ALS animals. *Exp. Neurol.* 2015, 267, 95–106. [CrossRef] [PubMed]  

86. Costa, J.; Streich, L.; Pinto, S.; Pronto-Laborinho, A.; Nimtz, M.; Conrado, H.S.; de Carvalho, M. Exploring cerebrospinal Fluid IgG N-Glycosylation as Potential Biomarker for Amyotrophic Lateral Sclerosis. *Mol. Neurobiol.* 2019. [CrossRef]  

87. von Neuhoff, N.; Oumeraci, T.; Wolf, T.; Kollewe, K.; Bewerunge, P.; Neumann, B.; Brors, B.; Bufler, J.; Wurster, U.; Schlegelberger, B.; et al. Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: Obstacles and perspectives in translating a novel marker panel to the clinic. *PLoS ONE* 2012, 7, e44401. [CrossRef]  

88. Robelin, L.; Gonzalez De Aguilar, J.L. Blood biomarkers for amyotrophic lateral sclerosis: Myth or reality? *Biomed. Res. Int.* 2014, 2014, 525097. [CrossRef]  

89. Su, X.W.; Simmons, Z.; Mitchell, R.M.; Kong, L.; Stephens, H.E.; Connor, J.R. Biomarker-based predictive models for prognosis in amyotrophic lateral sclerosis. *JAMA Neurol.* 2013, 70, 1505–1511. [CrossRef]  

90. Martinez, H.R.; Escamilla-Ocanas, C.E.; Tenorio-Pedraza, J.M.; Gonzalez-Garza, M.T.; Jaime-Perez, J.C.; Olguin-Ramirez, L.A.; Salazar-Marioni, S.; Gonzalez-Garza, M.T. Altered CSF cytokine network in amyotrophic lateral sclerosis patients: A pathway-based statistical analysis. *Cytokine* 2017, 90, 1–5. [CrossRef]  

91. Gurbuzova-Davis, S.; Ehrhart, J.; Sanberg, P.R.; Borlongan, C.V. Potential Role of Humoral IL-6 Cytokine in Mediating Pro-Inflammatory Endothelial Cell Response in Amyotrophic Lateral Sclerosis. *Int. J. Mol. Sci.* 2018, 19, 423. [CrossRef] [PubMed]  

92. Peake, J.M.; Della Gatta, P.; Suzuki, K.; Nieman, D.C. Cytokine expression and secretion by skeletal muscle cells: Regulatory mechanisms and exercise effects. *Exerc. Immunol. Rev.* 2015, 21, 8–25. [PubMed]  

93. Moreau, C.; Devos, D.; Brunaud-Danel, V.; Defebrve, L.; Perez, T.; Destee, A.; Tonnel, A.B.; Lassalle, P.; Just, N. Elevated IL-6 and TNF-alpha levels in patients with ALS: Inflammation or hypoxia? *Neurology* 2005, 65, 1958–1960. [CrossRef] [PubMed]  

94. Selmaoui, B.; Sackett-Lundeen, L.; Haus, E.; Touitou, Y. Large intra-individual variability of plasma cytokines in healthy young men: A two 24-h study over a month. *Biol. Rhythm Res.* 2016, 47, 267–273. [CrossRef]
95. Barschke, P.; Oeckl, P.; Steinacker, P.; Ludolph, A.; Otto, M. Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. *Expert Rev. Proteomics* **2017**, *14*, 769–777. [CrossRef] [PubMed]

96. Otto, M.; Bowser, R.; Turner, M.; Berry, J.; Brettschneider, J.; Connors, J.; Costa, J.; Cudkowicz, M.; Glass, J.; Jahn, O.; et al. Volcano Group Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotroph. Lateral Scler.* **2012**, *13*, 1–10. [CrossRef] [PubMed]

97. Mitumoto, H.; Factor-Litvak, P.; Andrews, H.; Goetz, R.R.; Andrews, L.; Rabkin, J.G.; McElhiney, M.; Nieves, J.; Santella, R.M.; Murphy, J.; et al. ALS COSMOS Study Group ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): Study methodology, recruitment, and baseline demographic and disease characteristics. *Amyotroph. Lateral Scler. Frontotemporal Degener.* **2014**, *15*, 192–203. [CrossRef]

98. Calvo, A.; Moglia, C.; Lunetta, C.; Marinou, K.; Ticozzi, N.; Ferrante, G.D.; Scialo, C.; Soraru, G.; Trojsi, F.; Conte, A.; et al. Factors predicting survival in ALS: A multicenter Italian study. *J. Neurol.* **2017**, *264*, 54–63. [CrossRef]

99. D’hulst, L.; Van Wehaaghe, D.; Chio, A.; Calvo, A.; Moglia, C.; Canosa, A.; Cistaro, A.; Willekens, S.M.; De Vocht, J.; Van Damme, P.; et al. Multicenter validation of [(18)F]-FDG PET and support-vector machine discriminant analysis in automatically classifying patients with amyotrophic lateral sclerosis versus controls. *Amyotroph. Lateral Scler. Frontotemporal Degener.* **2018**, *19*, 570–577. [CrossRef]

100. Pollari, E.; Savchenko, E.; Jaronen, M.; Kanninen, K.; Malm, T.; Wojciechowski, S.; Ahtoniemi, T.; Goldsteins, G.; Giniatullina, R.; Giniatullin, R.; et al. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. *J. Neuroinflamm.* **2011**, *8*, 74. [CrossRef]

101. Rando, A.; Gasco, S.; de la Torre, M.; Garcia-Redondo, A.; Zaragoza, P.; Toivonen, J.M.; Osta, R. Granulocyte Colony-Stimulating Factor Ameliorates Skeletal Muscle Dysfunction in Amyotrophic Lateral Sclerosis Mice and Improves Proliferation of SOD1-G93A Myoblasts in vitro. *Neurodegener Dis.* **2017**, *17*, 1–13. [CrossRef] [PubMed]

102. Johannesen, S.; Budeus, B.; Peters, S.; Iberl, S.; Meyer, A.L.; Kammermaier, T.; Wirkert, E.; Bruun, T.H.; Samara, V.C.; Schulte-Mattler, W.; et al. Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients. *Front. Neurol.* **2018**, *9*, 971. [CrossRef] [PubMed]

103. Otsmane, B.; Aebischer, J.; Moumen, A.; Raoul, C. Cerebrospinal fluid-targeted delivery of neutralizing anti-IFNgamma antibody delays motor decline in an ALS mouse model. *Neuroreport* **2014**, *25*, 49–54. [PubMed]

104. Korhonen, P.; Pollari, E.; Kanninen, K.M.; Savchenko, E.; Lehtonen, S.; Wojciechowski, S.; Pomeshchik, Y.; Van Den Bosch, L.; Goldsteins, G.; Koistinaho, J.; et al. Long-term interleukin-33 treatment delays disease onset and alleviates astrocytic activation in a transgenic mouse model of amyotrophic lateral sclerosis. *IBRO Rep.* **2019**, *6*, 74–86. [CrossRef] [PubMed]

105. Kiaei, M.; Petri, S.; Kipiani, K.; Gardian, G.; Choi, D.K.; Chen, J.; Calingasan, N.Y.; Schafer, P.; Muller, G.W.; Stewart, C.; et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. *J. Neurosci.* **2006**, *26*, 2467–2473. [CrossRef] [PubMed]

106. Neymotin, A.; Petri, S.; Calingasan, N.Y.; Wille, E.; Schafer, P.; Stewart, C.; Hensley, K.; Beal, M.F.; Kiaei, M. Lenalidomide (Revlimid) administration at symptom onset in a mouse model of amyotrophic lateral sclerosis. *Exp. Neurol.* **2009**, *220*, 191–197. [CrossRef] [PubMed]

107. Stommel, E.W.; Cohen, J.A.; Fadul, C.E.; Cogbill, C.H.; Graber, D.J.; Kingman, L.; Mackenzie, T.; Channon Smith, J.Y.; Harris, B.T. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. *Amyotroph Lateral Scler.* **2009**, *10*, 393–404. [CrossRef] [PubMed]

108. Han, Y.; Riplley, B.; Serada, S.; Naka, T.; Fujimoto, M. Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation. *PLoS ONE* **2016**, *11*, e0153399. [CrossRef] [PubMed]

109. Patin, F.; Baranek, T.; Vourc’h, P.; Nadal-Desbarats, L.; Goossens, J.F.; Marouillat, S.; Dessein, A.F.; Descat, A.; Hououm, B.M.; Bruno, C.; et al. Combined Metabolomics and Transcriptomics Approaches to Assess the IL-6 Blockade as a Therapeutic of ALS: Deleterious Alteration of Lipid Metabolism. *Neurotherapeutics* **2016**, *13*, 905–917. [CrossRef]

110. Kim, S.H.; Oh, K.W.; Jin, H.K.; Bae, J.S. Immune inflammatory modulation as a potential therapeutic strategy of stem cell therapy for ALS and neurodegenerative diseases. *BMB Rep.* **2018**, *51*, 545–546. [CrossRef]
111. Sheean, R.K.; McKay, F.C.; Cretney, E.; Bye, C.R.; Perera, N.D.; Tomas, D.; Weston, R.A.; Scheller, K.J.; Djouma, E.; Menon, P.; et al. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. *JAMA Neurol.* 2018, 75, 681–689. [CrossRef] [PubMed]

112. Thonhoff, J.R.; Beers, D.R.; Zhao, W.; Pleitez, M.; Simpson, E.P.; Berry, J.D.; Cudkowicz, M.E.; Appel, S.H. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. *Neurology. Neuroimmunol. Neuroinflamm.* 2018, 5, e465. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).